Filters:
770 Projects | 528 Researchers | $318,295,055 Invested
2024
Boston University
Rhoda Au, PhD
2023 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery: Validation of a Globally Scalable AD Screening Tool: A/T/dN
2024
Fujirebio Europe NV
Manu Vandijck
Plasma pTau217 detection with the LUMIPULSE G platform as indicator for Alzheimer’s Disease
2024
Neurotrack Technologies, Inc
Jordan Glenn, PhD
Digital Multimodal Neuropsychological Phenotyping for the Detection of Cognitive Decline in Aging Adults
2024
Coya Therapeutics
Fred Grossman, DO, FAPA
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 26-Week Study to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Subtype of Frontotemporal Lobar Degeneration (FTLD).
2024
Trustees of Indiana University
Timothy Richardson, Phd
Lead Optimization of SHIP1 Inhibitors and Biomarker Development for the Treatment of Alzheimer's Disease
2024
Johns Hopkins University
Jeffrey Rothstein, MD, PhD
Mitigating TDP-43 loss of function and disease initiation in FTD thru repair of the Nuclear Pore and CHMP7/ESCRT3 dysfunction.
2024
FINGERS Brain Health Institute
Miia Kivipelto, MD, PhD
Strategic Collaborative Framework for developing and testing innovative combination therapies, biomarkers, and digital solutions for precision prevention of cognitive decline and Alzheimer’s Disease and Related Dementias (previously: FINGERS Brain Health Institute - ADDF Memorandum of Understanding Planning Grant)
2024
University College London
Simon Mead, MD, FRCP, PhD
Biomarker-driven phenotyping for Alzheimer's disease and related dementia
2023
Metro International Biotech
David Livingston, PhD
Nicotinamide Mononucleotide in Patients with Alzheimer's Disease
2023
ADmit Therapeutics S.L.
Marta Barrachina, PhD, MBA
MAP-AD, a revolutionary Methylation Profiling approach for early diagnosis of Alzheimer’s Disease
View More